Century Therapeutics IPSC
NASDAQ IPSC
$1.65 -0.02 (-1.20%)
At close: Sep 29, 2026 · 4:00 PM EDT

Century Therapeutics (IPSC) EBIT Margin (2022 - 2025)

Updated

Century Therapeutics' EBIT Margin was -15.82% in FY2025, up 2080.66 percentage points from -2096.48% in FY2024.

Analysis

Century Therapeutics (IPSC) EBIT Margin (2022 - 2025) Analysis & Trends

From FY2022 onward, Century Therapeutics has reported EBIT Margin for 4 years.

  • EBIT Margin shows a three-year change of +2558.35 percentage points (FY2022 to FY2025).
  • Per Business Quant data, EBIT Margin in earlier years was -2096.48% in FY2024 (+4460.39 pp), -6556.87% in FY2023 (-3982.70 pp) and -2574.17% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 Century Therapeutics 301.51 Mn -202.86 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 67.95%
Dec 31, 2024 -893.46%
Sep 30, 2024 -4,398.10%
Jun 30, 2024 -4,507.78%
Mar 31, 2024 -3,661.87%
Dec 31, 2023 -16,329.10%
Sep 30, 2023 -24,071.62%
Jun 30, 2023 -35,431.31%
Mar 31, 2023 -1,865.17%
Dec 31, 2022 -6,392.71%
Sep 30, 2022 -1,427.07%
Jun 30, 2022 -2,245.77%
Mar 31, 2022 -3,538.37%
API Access

Century Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=IPSC&period=max&api_key=YOUR_API_KEY